This segment focuses on the development and manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. Avid Bioservices provides comprehensive services, including upstream and downstream process development, optimization, and scale-up. The company utilizes advanced bioreactor technologies and purification methods to produce monoclonal antibodies and recombinant proteins. This segment serves biotechnology and pharmaceutical companies, supporting their clinical and commercial manufacturing needs. The patient impact is significant, as these products often address unmet medical needs in areas like oncology, immunology, and rare diseases. Avid's market positioning is strong due to its expertise in CGMP manufacturing and its ability to deliver high-quality products. Future opportunities include expanding capacity and capabilities to meet growing demand for biologics. Regulatory and clinical aspects are critical, with a focus on compliance with FDA and other regulatory bodies. Partnerships with technology providers and research institutions are essential for staying at the forefront of innovation.

Avid Bioservices offers a range of process development services to support the manufacturing of biopharmaceutical drug substances. This segment includes upstream and downstream process development, optimization, analytical method development, and characterization. The company utilizes advanced technologies such as cell culture optimization, chromatography, and filtration to develop robust and scalable manufacturing processes. These services are crucial for ensuring the efficient and cost-effective production of high-quality drug substances. The therapeutic areas served are diverse, including oncology, immunology, and infectious diseases. The patient impact is realized through the acceleration of drug development timelines and the improvement of product quality. Avid's competitive advantage lies in its experienced team, state-of-the-art facilities, and commitment to quality. Future opportunities include expanding into new modalities and technologies, such as cell and gene therapy. Regulatory and clinical aspects are addressed through adherence to CGMP guidelines and support for regulatory submissions. Partnerships with clients and technology providers are essential for delivering innovative solutions.